Despite pharma’s one-year underperformance, Sharekhan sees strong revenue growth and identifies five top stocks with 9–16% upside potential.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets
Despite pharma’s one-year underperformance, Sharekhan sees strong revenue growth and identifies five top stocks with 9–16% upside potential.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets